Maldonado Genessis, Guerrero Roberto, Intriago Maria, Rios Carlos
Internal Medicine Residency Program, Loyola MacNeal Hospital, Berwyn, IL, USA.
Rheumatology Department, School of Medicine, Universidad Espiritu Santo, Guayaquil, Ecuador.
Rev Colomb Reumatol. 2022 Jun;29:S84-S87. doi: 10.1016/j.rcreu.2021.06.003. Epub 2021 Jul 5.
The SARS-CoV-2 virus was first identified in December 2019, the infection was named COVID-19. The initial symptoms and evolution of the disease have been described over the past year. The virus has been shown to increase the risk of thromboembolic events due to the hypercoagulable state triggered by systemic endothelial inflammation. We present the case of a patient with a history of rheumatoid arthritis under prolonged treatment with tofacitinib, who presented COVID-19 and subsequently developed a hypercoagulable state of approximately 6 months' duration. The possible association between viral infection and the use of tofacitinib is debated.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）于2019年12月首次被发现，该感染被命名为2019冠状病毒病（COVID-19）。在过去一年中已经描述了该疾病的初始症状和演变过程。由于全身性内皮炎症引发的高凝状态，已表明该病毒会增加血栓栓塞事件的风险。我们报告一例有类风湿关节炎病史且长期接受托法替布治疗的患者，该患者感染了COVID-19，随后出现了持续约6个月的高凝状态。病毒感染与托法替布使用之间的可能关联存在争议。
